Personalizing Medicine and Technologies to Address the Experiences and Needs of People with Multiple Sclerosis.
fatigue management
lived experience
multiple sclerosis
personalized medicine
uncertainty
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
12 Aug 2021
12 Aug 2021
Historique:
received:
21
05
2021
revised:
03
08
2021
accepted:
10
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
There is enormous variation in the manifestations of disease experienced by people with multiple sclerosis (PwMS). While this variation makes personalized medicine an attractive goal, there are many challenges to be overcome before this opportunity can be realized. Personalized medicine often focuses on targeted therapies and detailed monitoring, but we also need to recognize that there will be variation in acceptance of these approaches by different PwMS. In other words, deep personalization of medicine will encompass targeted therapy, precision monitoring, tailored to variation in personal attitudes to these transformations in health care. In order to meet the promise of personalized medicine for MS, understanding the experiences of PwMS is necessary both to aid in the uptake of personalized medicine, and to ensure that personalized approaches to monitoring disease and treatment provide a net benefit to PwMS rather than placing additional burdens and stressors on them. Here, we describe recent research that identified five experiential themes for PwMS, and then interpret these themes according to the foundations of personalized medicine to provide a road map for implementation of personalized medicine solutions for PwMS.
Identifiants
pubmed: 34442434
pii: jpm11080791
doi: 10.3390/jpm11080791
pmc: PMC8401762
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Australian National University
ID : Grand Challenge
Références
Eur J Public Health. 2016 Feb;26(1):60-4
pubmed: 26136462
JMIR Res Protoc. 2018 Jul 27;7(7):e10961
pubmed: 30054262
PLoS One. 2016 Nov 1;11(11):e0164992
pubmed: 27802296
Mult Scler. 2017 Mar;23(3):362-369
pubmed: 27672137
Health Expect. 2020 Oct;23(5):1007-1027
pubmed: 32578287
Clin Immunol. 2015 Nov;161(1):51-8
pubmed: 26143623
Mult Scler. 2021 Jun;27(7):983-988
pubmed: 32672087
BMC Med. 2012 Oct 04;10:116
pubmed: 23035757
Int J Mol Sci. 2016 Oct 17;17(10):
pubmed: 27763513
Disabil Rehabil. 2018 Jun;40(12):1434-1442
pubmed: 28322588
J Med Internet Res. 2017 Nov 01;19(11):e367
pubmed: 29092808
Science. 2015 Jul 17;349(6245):255-60
pubmed: 26185243
N Engl J Med. 2016 Aug 25;375(8):711-3
pubmed: 27557298
EMBO Rep. 2015 Feb;16(2):133-6
pubmed: 25550405
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
EPMA J. 2019 Nov 22;10(4):425-436
pubmed: 31832116
Front Immunol. 2021 May 03;12:669811
pubmed: 34012452
Mult Scler. 2012 May;18(5):552-6
pubmed: 22492131